Dr Stefano Portolano, M.D., is the new Chief Executive Officer of Azafaros and has been appointed to the Board of Directors of the Dutch company.

At the beginning of June, Sidonie Fabre strengthens Advent France Biotechnology (AFB) as new Chief Financial Officer.

Tom Graney, until now CFO of Belgian Oxurion nv, took over from CEO Patrik De Haes. De Haes becomes Non-executive Chairman of the Biopharmaceutical company, spezialised in retinal disorders.

Barcelona-based Aelix Therapeutics has appointed Dr Melanie Rolli as CEO. Her predecessor, Dr Jose Luis Cabero, had decided to step down from executive positions at Aelix

Belgium-based Celyad has had a new CMO since April: Dr Charles Morris.

The Venture Capital Company Kurma Partners, based in Paris and Munich, appointed Jean-Francois Rivassou as new Partner.

Francesco Maria Lavino has been appointed as Chief Executive Officer of F2G Ltd., a biopharmaceutical company, based in UK and Austria, and specialised in fungal infections.

At the beginning of March, Dr Sophie Biguenet has been the new Chief Medical Officer of Paris-based Abivax SA.

Torben Osterlund is the new Chief Scientific Officer of the Dutch biotech company Toxys B.V., based in Leiden

Mads Krogsgaard Thomsen, CSO at Novo Nordisk, will take up the position as CEO of the Novo Nordisk Foundation effective from 1 March 2021.